So here's what nobody was talking about at the start of November: healthcare stocks absolutely crushing it while the AI trade falls apart.
Sure, everyone's watching Palantir Technologies Inc. (PLTR) and CoreWeave Inc. (CRWV) get hammered after posting triple-digit gains earlier this year. These AI darlings are facing the kind of corrections that make growth investors question their life choices. But quietly, in the background, healthcare is having a moment.
The Healthcare Select Sector SPDR Fund (XLV) is up nearly 6% month-to-date, its best monthly performance since January. That makes it the top-performing sector in the S&P 500 for November so far. Not flashy AI infrastructure. Not semiconductor plays. Healthcare.
Meanwhile, the Nasdaq 100 is on pace for its worst November since 2008. The Technology Select Sector SPDR Fund (XLK) has shed more than 5% this month, weighed down by concerns over supply constraints and valuation excesses in artificial intelligence names. When you add it all up, this divergence is shaping up to be one of the largest monthly outperformance gaps between healthcare and tech since 2002.
The Money Is Moving
Flow data tells the story even more clearly. According to Bank of America's latest Flow Show report from chief investment strategist Michael Hartnett, healthcare just recorded its largest weekly inflow since January 2021. That's not noise—that's a rotation.
In a market dealing with uncertainty, stretched valuations, and cooling expectations for rate cuts, investors are increasingly treating healthcare as a defensive haven. It's the place you go when you're worried about what happens next but still need to be invested.
Why Healthcare Makes Sense Right Now
Part of this is just math. Despite this week's tech pullback, technology stocks still trade at expensive multiples. The Vanguard S&P 500 ETF (VOO) currently trades at a forward P/E ratio of 23x, but the XLK sits even higher at around 30x.
Healthcare? The XLV trades at 20x forward earnings. That makes it one of the cheapest sectors in the market, right alongside financials, utilities, and energy. When you're paying 30x for tech and 20x for healthcare, the risk-reward calculation starts to shift—especially if you're not convinced that rates are coming down as fast as everyone thought three months ago.
If inflation makes a surprise comeback or rates stay higher for longer, expensive growth stocks could remain under pressure. Meanwhile, sectors with strong cash flows, stable margins, and lower multiples might actually hold up. That's the healthcare pitch right now, and judging by the flows, people are buying it.
Who's Winning Inside Healthcare
The gains aren't evenly distributed, but the winners are impressive. Eli Lilly and Co. (LLY) is up 19.62% month-to-date through November 14. Henry Schein Inc. (HSIC) gained 13.88%, while Amgen Inc. (AMGN) climbed 13.51%. Incyte Corp. (INCY) added 13.35%, and The Cigna Group (CI) rose 10.85%.
Rounding out the leaders, STERIS plc (STE) gained 10.41% and IDEXX Laboratories Inc. (IDXX) picked up 10.20%. These are solid, double-digit moves in a market where tech investors are just trying to stop the bleeding.
The Bigger Picture
This rotation might not last forever. Healthcare doesn't have the explosive upside potential of AI stocks when things are going well. But right now, "going well" is not the vibe in technology land. Supply chain concerns are real, valuations are stretched, and investors are starting to wonder if we got a little ahead of ourselves on the AI infrastructure buildout.
Healthcare doesn't solve those problems, but it sidesteps them entirely. You get exposure to companies with stable demand, reasonable valuations, and business models that don't depend on predicting the exact trajectory of GPU availability or data center construction timelines.
So while everyone's debating whether the AI bubble is bursting, healthcare is just quietly putting up numbers. Sometimes the best trade is the one nobody's talking about.
